Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine

Journal of Infectious Diseases

Volumn 180, Issue 6, 1999, Pages 2018-2022

  Frey, Sharon ^a   Dagan, Ron ^b   Ashur, Yaffa ^c   Chen, Xiao Q ^d   Ibarra, Jose ^e   Kollaritsch, Herwig ^g   Mazur, Mark H ^f   Poland, Gregory A ^h   Reisinger, Keith ⁱ   Walter, Emmanuel ^k   Van Damme, Pierre ^l   Braconier, Jean H ⁿ   Uhnoo, Ingrid ^m   Wahl, Martin ⁿ   Blatter, Mark M ⁱ   Clements, Dennis ^k   Greenberg, David ^b   Jacobson, Robert M ^h   Ragnar Norrby, S ⁿ   Rowe, Mina ^c   Shouval, Daniel ^c   Simmons, Sue S ^k   Van Hattum, Jan ^d   Wennerholm, Solveig ⁿ   O'Brien Gress, Jacqueline ^j   Chan, Ivan ^j   Kuter, Barbara ^j   more..

^a SAINT LOUIS UNIVERSITY   (United States)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e Future HealthCare   (United States)

^f Los Robles Regional Medical Center   (United States)

^g UNIVERSITY OF VIENNA   (Austria)

^h MAYO CLINIC   (United States)

ⁱ Primary Physicians Research   (United States)

^j MERCK RESEARCH LABORATORIES   (United States)

^k DUKE UNIVERSITY MEDICAL CENTER   (United States)

^l UNIVERSITY OF ANTWERP   (Belgium)

^m UPPSALA UNIVERSITY HOSPITAL   (Sweden)

ⁿ SUIÖstra ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ADOLESCENT; ADULT; ANTIBODY PRODUCTION; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEPATITIS A; HEPATITIS B; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

ADOLESCENT; ADULT; CHILD; FEMALE; HEPATITIS A VACCINES; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATOVIRUS; HUMANS; MALE; VACCINATION; VACCINES, COMBINED; VIRAL HEPATITIS VACCINES;

EID: 0032731101     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315119     Document Type: Article

References (15)

1. 1. Nalin D, Brown L, Kuter B, et al. Inactivated hepatitis A vaccine in childhood: implications for disease control. Vaccine 1993;11(Suppl 1):S15-7.
2. 2. Hilleman MR. Hepatitis and hepatitis A vaccine: a glimpse of history. J Hepatol 1993;18(Suppl 2):S5-10.
3. 3. Werzberger A, Kuter B, Shouval D, et al. Anatomy of a trial: a historical view of the Monroe inactivated hepatitis A protective efficacy trial. J Hepatol 1993;18(Suppl 2):S46-50.
4. 4. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep 1996;45(RR-15):1-30.
5. 5. Szmuness W, Stevens CE, Harley EJ, Zang EA, Taylor PE, Alter HJ. The immune response of healthy adults to a reduced dose of hepatitis B vaccine. J Med Virol 1981;8:123-9.
6. 6. Goh KT, Tan KL, Kong KH, Oon CJ, Chan SH. Comparison of the immune response of four different dosages of a yeast-recombinant hepatitis B vaccine in Singapore children: a four-year follow-up study. Bull WHO 1992;70:233-9.
7. 7. Milne A, Brawner TA, Dumbill PC, Kawachi I, Pearce NE. Comparison of immunogenicity of reduced doses of two recombinant DNA hepatitis B vaccines in New Zealand children. J Med Virol 1989;27:264-7.
8. 8. Butterly L, Watkins E, Dienstag JL. Recombinant yeast-derived hepatitis B vaccine in healthy adults: safety and two-year immunogenicity of early investigative lots of vaccine. J Med Virology 1989;27:155-9.
9. 9. Milne A, Moyes CD, Allwood GK, Pearce NE, Krugman S. Antibody responses to recombinant, yeast-derived hepatitis B vaccine in teenage New Zealand children. N Z Med J 1988;101:67-9.
10. 10. Zajac BA, West DJ, McAleer WJ, Scolnick EM. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect 1986; 13(Suppl A):39-45.
11. 11. Marsano LS, West DJ, Chan I, et al. A two-dose hepatitis B vaccine regimen: proof of priming and memory responses in young adults. Vaccine 1998; 16:624-9.
12. 12. Wiens B, Heyse J, Matthews H. Similarity of three treatments, with application to vaccine development. In: Proceedings of the Biopharmaceutical Section, annual meeting of the American Statistical Association, Chicago, 4-8 August 1996. Alexandria, VA: American Statistical Association, 1996; 203-6.
13. 13. Farrington CP, Manning G. Test statistics and sample size formulae for comparative binominal trials with null hypothesis of non-zero risk difference or non-comparative non-unity relative risk. Stat Med 1990;9: 1447-54.
14. 14. Leroux-Roels G, Moreau W, Desombere I, Safary A. Safety and immunogenicity of a combined hepatitis A and hepatitis B vaccine in young healthy adults. Scand J Gastroenterol 1996;31:1027-31.
15. 15. Ambrosch F, Wiedermann G, Andre FE, et al. Clinical and immunological investigation of a new combined hepatitis A and hepatitis B vaccine. J Med Virol 1994;44:452-6.